Related Experiment Video
Updated: Apr 19, 2026

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
Published on: July 24, 2016
Congenital and postnatal CMV and EBV acquisition in HIV-infected Zimbabwean infants
Hlanai Gumbo1, Bernard Chasekwa1, James A Church2
1Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe.
Insights
Cytomegalovirus (CMV) and Epstein Barr virus (EBV) co-infections are common in HIV-infected infants in sub-Saharan Africa. However, neither CMV nor EBV co-infection was found to increase mortality in these infants.
Area of Science:
- Pediatrics
- Infectious Diseases
- Virology
Background:
- HIV-infected infants in sub-Saharan Africa experience rapid disease progression.
- Co-infection with cytomegalovirus (CMV) or Epstein Barr virus (EBV) was hypothesized to increase mortality in this vulnerable population.
Purpose of the Study:
- To investigate the prevalence of CMV and EBV co-infections in HIV-infected infants.
- To determine the impact of CMV and EBV co-infections on mortality in HIV-infected infants.
Main Methods:
- Real-time PCR was used to test 257 antiretroviral therapy-naïve HIV-infected infants for CMV and EBV at 6 weeks of age.
- Birth samples were analyzed when available to differentiate congenital from postnatal infections.
- Kaplan-Meier and Cox proportional hazards models were employed to assess mortality risk associated with co-infections up to 6 months of age.
Main Results:
- By 6 weeks, 79% of infants were CMV-positive, with 11% having congenital CMV and 42% having postnatal CMV.
- By 6 months, postnatal CMV infection showed no significant increase in mortality (aHR 1.1; 95% CI 0.6, 2.2).
- By 6 weeks, 13% of infants had EBV co-infection, with 2% congenital and 7% postnatal; neither was associated with increased mortality by 6 months (aHR 0.8; 95% CI 0.3, 2.3).
Conclusions:
- The majority of HIV-infected infants acquired CMV by 6 weeks, and EBV co-infection occurred earlier than anticipated.
- A high prevalence of congenital CMV and the identification of congenital EBV infection (newly reported in Africa/HIV context) were observed.
- Neither CMV nor EBV co-infection demonstrated a statistically significant association with increased mortality in HIV-infected infants within the study period.
Background:
HIV-infected infants in sub-Saharan Africa have rapid disease progression. We hypothesized that co-infection with cytomegalovirus (CMV) or Epstein Barr virus (EBV) increases mortality in HIV-infected infants.
Methods:
257 antiretroviral therapy-naïve HIV-infected Zimbabwean infants were tested for CMV and EBV at 6 weeks of age by real-time PCR; if positive, birth samples were retrieved where available to distinguish congenital and postnatal infection. The impact of co-infection on mortality through 6 months was estimated using Kaplan-Meier and Cox proportional hazards methods.
Results:
At 6 weeks, 203/257 (79%) HIV-infected infants were CMV-positive; 27 (11%) had congenital CMV, 108 (42%) postnatal CMV and 68 (26%) indeterminate timing of infection. By 6 months, 37/108 (34%) infants with postnatal CMV versus 16/54 (30%) CMV-negative infants died (adjusted hazard ratio (aHR) 1.1 [95%CI 0.6, 2.2]). At 6 weeks, 33/257 (13%) HIV-infected infants had EBV co-infection; 6 (2%) had congenital EBV, 18 (7%) postnatal EBV and 9 (4%) indeterminate timing of infection. By 6 months, 5/18 (28%) infants with postnatal EBV versus 72/224 (32%) EBV-negative infants died (aHR 0.8 [95%CI 0.3, 2.3]).
Conclusions:
The vast majority of HIV-infants had acquired CMV by 6 weeks, and EBV co-infection occurred earlier than expected, with one in eight HIV-infected infants positive for EBV by 6 weeks. There was a high prevalence of congenital CMV infection and we identified 6 infants with congenital EBV infection, which has not previously been reported in Africa or in the context of HIV infection. Neither CMV nor EBV co-infection was associated with increased mortality.
More Related Videos
05:53Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
Related Concept Videos
Cytomegalovirus Disease
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Viral Mutations
Sexually Transmitted Infections